SCHEMBL2926459

SCHEMBL2926459

Cc1cc(C(=O)O)cc(C(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.61
HCAR1 Q9BXC0 1/20 0.53
CES2 O00748 1/20 0.52
MRGPRX4 Q96LA9 2/20 0.51
RXRA P19793 3/20 0.50
RXRB P28702 3/20 0.50
RXRG P48443 1/20 0.50
TAS2R14 Q9NYV8 1/20 0.48
SRD5A2 P31213 3/20 0.46
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
NOTUM Q6P988 1/20 0.42
ADCY8 P40145 1/20 0.42
ADCY1 Q08828 1/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30240792 1.00 TPMT (0.61) TPMTHCAR1CES2MRGPRX4RXRA
SCHEMBL18198911 0.89 RXRA (0.57) TPMTHCAR1CES2MRGPRX4RXRA
SCHEMBL16809141 0.85 RXRA (0.62) TPMTHCAR1CES2MRGPRX4RXRA
SCHEMBL545011 0.85 CES2 (0.62) CES2MRGPRX4RXRARXRBRXRG
SCHEMBL503980 0.85 CES2 (0.70) CES2MRGPRX4RXRARXRBRXRG
SCHEMBL17322692 0.85 CES2 (0.59) TPMTCES2MRGPRX4RXRARXRB
SCHEMBL17586584 0.84 CES2 (0.57) CES2RXRARXRBRXRGTAS2R14
SCHEMBL7786247 0.84 CES2 (0.52) TPMTCES2RXRARXRBRXRG
SCHEMBL28119413 0.83 CES2 (0.67) CES2MRGPRX4RXRARXRBRXRG
Hydrochloric Acid SCHEMBL7485970 0.83 CES2 (0.67) CES2MRGPRX4RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116535365-A Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer ITEOS比利时公司 2023-08-04 CN claimed
US-20250353853-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-11-20 US disclosed
EP-4532476-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-04-09 EP disclosed
US-20240241444-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2024-07-18 US disclosed
US-20240241444-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2024-07-18 US disclosed
US-12038689-B2 Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, and method for manufacturing electronic device FUJIFILM CORPORATION (JP) 2024-07-16 US disclosed
US-20240027908-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2024-01-25 US disclosed
WO-2023227734-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-30 WO disclosed
EP-4282862-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-29 EP disclosed
US-11656548-B2 Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, mask blank with resist film, method for producing photomask, and method for manufacturing electronic device FUJIFILM CORPORATION (JP) 2023-05-23 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 US disclosed
US-20070082907-A1 Peroxisome proliferator activated receptor modulators ELI LILLY AND COMPANY (IN) 2007-04-12 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
EP-1697304-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-09-06 EP disclosed
WO-2005054176-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 TPMT 2300/4885HCAR1 2132/4885CES2 4137/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR TPMT 1086/4885HCAR1 187/4885CES2 1486/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR TPMT 1097/4885HCAR1 174/4885CES2 1509/4885
US-20070082907-A1 Peroxisome proliferator activated receptor modulators PPARG, PPARA, PPARD TPMT 3539/4885HCAR1 255/4885CES2 1788/4885
US-20250353853-A1 FLAVIVIRUS INHIBITORS SPINT2, EIF2AK2, DDX5 TPMT 921/4885HCAR1 4704/4885CES2 1372/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA TPMT 283/4885HCAR1 1156/4885CES2 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.